Abstract 278: Artificial intelligence accelerate drug discovery

Abstract

Abstract Drug discovery is resource intensive, and involves typical timelines of 10-20 years and costs that range from US$0.5 billion to US$2.6 billion. Artificial intelligence (AI) has recently started to gear-up its application in various sectors of the society and the pharmaceutical industry as a frontrunner beneficiary.Artificial intelligence can accelerate drug discovery and reduce costs by facilitating the rapid screening and identification of compounds. We have developed DM-AI drug discovery platform, including convolutional neural networks, decision treealgorithm, reinforcement learning, generative adversarial networks, big data, and knowledge graphs, along with structure and ligand-based high-throughput virtual screening , for new drug discovery and development. DM-AI optimizes biological activity,toxicity,physicochemical property. We used DM-AI to discover potent inhibitors of SHP2, PIM1, DNA-PK, kinases target implicated in solid tumor and other diseases.We started to train a biological activity prediction model on a database of the given target kinase inhibitors (positive set) and non-kinase targets molecules (negative set), and then predicted the activity of existing million data sets, obtained an initial output of thousands structures. We then evaluated these structures using a pharmacophore reward model on the basis of virtual chemical spaces of kinase inhibitors in complex with target protein. To narrow our focus to a smaller set of molecules for analysis, compounds with higher score were filtered to remove patents and applications molecules, also remove molecules bearing structural alerts and reactive groups.By day 7 after target selection, We had selected dozens structures with structural diversity for experimental validation. and by day 28, they were tested for in vitro inhibitory activity in an enzymatic kinase assay, active compounds accounted for up to 65% in some target models. This illustrates the utility of our DM-AI drug discovery platform for the successful, rapid discovery of drug candidates. Citation Format: Weidong Xie, Xing Cheng, Zhengfang Ding, Riqiang Deng, Dawei Gu. Artificial intelligence accelerate drug discovery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 278.